Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 22, 2015

Primary Completion Date

March 28, 2016

Study Completion Date

April 22, 2016

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

LDV/SOF

90/400 mg FDC tablet administered orally

Trial Locations (6)

San Francisco

Chicago

New Orleans

Detroit

New York

Dallas